Catalyst Wire Dossier Catalyst Wire Dossier

Anti-Bet v 1 monoclonal antibody

bet v 1-targeted monoclonal antibody · Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-Bet v 1 monoclonal antibody, covering 2024-11-19 to 2024-11-19. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants [Phase 2]

See pricing